Last 7 days
-4.4%
Last 30 days
-31.1%
Last 90 days
-40.0%
Trailing 12 Months
-10.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 127.1B | 26.3B | 0.79% | 2.78% | 19.4 | 4.83 | 1.32% | 11.18% |
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.92% | 26.77% | 12.8 | 3.83 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.59% | 3.19% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
BBIO | 2.2B | 107.9M | 21.83% | 38.60% | -4.63 | 20.79 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.55% | -48.21% | -7.49 | 35.56 | 17.51% | 22.00% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -7.70% | -49.25% | -4.81 | 11.47 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -17.00% | 22.02% | -7.14 | 159.78 | 131.81% | -45.39% |
FATE | 524.4M | 96.3M | -14.58% | -86.07% | -1.86 | 5.45 | 72.44% | -32.79% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
SGMO | 276.9M | 111.3M | -42.96% | -71.96% | -1.44 | 2.49 | 0.54% | -7.86% |
VXRT | 101.6M | 107.0K | -17.23% | -85.52% | -0.94 | 949.93 | -88.00% | -52.91% |
IBIO | 26.0M | - | 40.00% | -84.44% | -0.32 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 13.7% | 660 | 581 | 487 | 472 | 443 |
S&GA Expenses | 20.1% | 144 | 120 | 98.00 | 53.00 | 50.00 |
R&D Expenses | 23.0% | 67.00 | 54.00 | 46.00 | 39.00 | 36.00 |
Costs and Expenses | 18.6% | 393 | 331 | 246 | 171 | 167 |
EBITDA | 8.1% | 272 | 252 | 245 | 305 | - |
EBITDA Margin | -5.0% | 0.41* | 0.43* | 0.50* | 0.65* | - |
Earnings Before Taxes | 6.9% | 249 | 233 | 233 | 295 | 249 |
EBT Margin | -6.0% | 0.38* | 0.40* | 0.48* | 0.63* | - |
Interest Expenses | 17.4% | 17.00 | 14.00 | 9.00 | 7.00 | 8.00 |
Net Income | -4.3% | 202 | 211 | 366 | 435 | 403 |
Net Income Margin | -15.8% | 0.31* | 0.36* | 0.75* | 0.92* | - |
Free Cahsflow | -0.9% | 235 | 238 | 290 | 287 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.2% | 1,842 | 1,865 | 1,781 | 1,162 | 1,104 |
Current Assets | 13.1% | 739 | 653 | 542 | 989 | 926 |
Cash Equivalents | 59.1% | 234 | 147 | 91.00 | 118 | 119 |
Inventory | -3.1% | 100 | 103 | 98.00 | 48.00 | 54.00 |
Goodwill | 105.1% | 409 | 199 | 199 | - | - |
Current Liabilities | 19.6% | 131 | 109 | 200 | 112 | 117 |
Long Term Debt | 30.1% | 1,493 | 1,147 | 788 | 787 | - |
LT Debt, Current | 0.1% | 13.00 | 13.00 | 99.00 | 90.00 | 89.00 |
LT Debt, Non Current | 89.4% | 1,491 | 787 | - | - | - |
Shareholder's Equity | 75.1% | 170 | 97.00 | 293 | 260 | 197 |
Retained Earnings | 67.5% | 143 | 86.00 | 24.00 | 1.00 | -58.91 |
Additional Paid-In Capital | 107.7% | 27.00 | 13.00 | 271 | 262 | 256 |
Accumulated Depreciation | 9.7% | 15.00 | 14.00 | 13.00 | 13.00 | - |
Shares Outstanding | 0.0% | 135 | 135 | 138 | 138 | 137 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 0.0% | 240 | 240 | 292 | 289 | 299 |
Share Based Compensation | 9.4% | 24.00 | 22.00 | 21.00 | 21.00 | 21.00 |
Cashflow From Investing | 37.9% | -487 | -784 | -800 | -410 | -406 |
Cashflow From Financing | 81.2% | 362 | 200 | 152 | -260 | 78.00 |
Buy Backs | -25.0% | 200 | 267 | 86.00 | 151 | - |
78.8%
17.7%
0.4%
Y-axis is the maximum loss one would have experienced if Halozyme Therapeutics was unfortunately bought at previous high price.
19.1%
21.4%
13.2%
27.6%
FIve years rolling returns for Halozyme Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 18.37 | 33,256,800 | 80,533,800 | 0.09% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 13,415 | 43,415 | -% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | new | - | 259,805 | 259,805 | 0.04% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 228 | 1,476,000 | 1,871,000 | 0.01% |
2023-02-28 | Voya Investment Management LLC | reduced | -6.39 | 3,916,680 | 15,203,700 | 0.02% |
2023-02-24 | SRS Capital Advisors, Inc. | reduced | -18.42 | -236 | 1,764 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -1,487,000 | - | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 9.97 | 602,000 | 1,633,000 | 0.02% |
2023-02-21 | NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | reduced | -37.12 | -75,010 | 711,990 | 0.02% |
2023-02-21 | MACQUARIE GROUP LTD | added | 1.97 | 47,174,000 | 148,239,000 | 0.17% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 10, 2023 | invesco ltd. | 5.2% | 7,036,951 | SC 13G | |
Feb 10, 2023 | blackrock inc. | 14.2% | 19,196,061 | SC 13G/A | |
Feb 10, 2023 | artisan partners limited partnership | 5.3% | 7,140,953 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.84% | 13,303,847 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G | |
Feb 04, 2022 | artisan partners limited partnership | 6.8% | 9,505,768 | SC 13G/A | |
Jan 28, 2022 | blackrock inc. | 13.8% | 19,439,863 | SC 13G/A | |
Feb 12, 2021 | bb biotech ag | 2.9% | 3,970,000 | SC 13G/A | |
Feb 10, 2021 | artisan partners limited partnership | 7.6% | 10,284,136 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 51.42 49.09% | 82.89 140.33% | 243.75 606.73% | 417.25 1109.77% | 617.69 1690.92% |
Current Inflation | 47.09 36.53% | 74.47 115.92% | 212.88 517.22% | 358.73 940.10% | 526.84 1427.52% |
Very High Inflation | 41.74 21.02% | 64.31 86.46% | 176.68 412.26% | 291.29 744.56% | 423.03 1126.53% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 24, 2023 | ARS | ARS | |
Mar 24, 2023 | DEF 14A | DEF 14A | |
Mar 24, 2023 | DEFA14A | DEFA14A | |
Mar 16, 2023 | 8-K | Current Report | |
Mar 13, 2023 | 8-K | Current Report | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 4 | Insider Trading | |
Feb 23, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-09 | Torley Helen | sold | -427,270 | 42.727 | -10,000 | president and ceo |
2023-03-09 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-08 | Torley Helen | sold | -432,590 | 43.259 | -10,000 | president and ceo |
2023-03-08 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-07 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-07 | Torley Helen | sold | -454,690 | 45.469 | -10,000 | president and ceo |
2023-03-01 | Torley Helen | gifted | - | - | -10,000 | president and ceo |
2023-03-01 | Henderson Jeffrey William | sold | -477,100 | 47.71 | -10,000 | - |
2023-02-28 | Henderson Jeffrey William | sold | -485,100 | 48.51 | -10,000 | - |
2023-02-27 | LaBarre Michael J. | sold | -495,483 | 49.5483 | -10,000 | svp, chief technical officer |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Total revenues | $ 660,116 | $ 443,310 | $ 267,594 |
Operating expenses: | |||
Cost of sales | 139,304 | 81,413 | 43,367 |
Amortization of intangible assets | 43,148 | 0 | 0 |
Research and development | 66,607 | 35,672 | 34,236 |
Selling, general and administrative | 143,526 | 50,323 | 45,736 |
Total operating expenses | 392,585 | 167,408 | 123,339 |
Operating income | 267,531 | 275,902 | 144,255 |
Other income (expense): | |||
Investment and other income, net | 1,046 | 1,102 | 5,425 |
Induced conversion expense related to convertible notes | (2,712) | (20,960) | 0 |
Interest expense | (16,947) | (7,526) | (20,378) |
Net income before income taxes | 248,918 | 248,518 | 129,302 |
Income tax expense (benefit) | 46,789 | (154,192) | 217 |
Net income | $ 202,129 | $ 402,710 | $ 129,085 |
Net income per share: | |||
Basic (USD per share) | $ 1.48 | $ 2.86 | $ 0.95 |
Diluted (USD per share) | $ 1.44 | $ 2.74 | $ 0.91 |
Shares used in computing net income per share: | |||
Basic (shares) | 136,844 | 140,646 | 136,206 |
Diluted (shares) | 140,608 | 146,796 | 141,463 |
Royalties | |||
Revenues: | |||
Total revenues | $ 360,475 | $ 203,900 | $ 88,596 |
Product sales, net | |||
Revenues: | |||
Total revenues | 191,030 | 104,224 | 55,987 |
Revenues under collaborative agreements | |||
Revenues: | |||
Total revenues | $ 108,611 | $ 135,186 | $ 123,011 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 234,195 | $ 118,719 |
Marketable securities, available-for-sale | 128,599 | 622,203 |
Accounts receivable, net and other contract assets | 231,072 | 90,975 |
Inventories | 100,123 | 53,908 |
Prepaid expenses and other current assets | 45,024 | 40,482 |
Total current assets | 739,013 | 926,287 |
Property and equipment, net | 75,570 | 8,794 |
Prepaid expenses and other assets | 26,301 | 13,414 |
Goodwill | 409,049 | 0 |
Intangible assets, net | 546,652 | 0 |
Deferred tax assets, net | 44,426 | 155,434 |
Restricted cash | 500 | 500 |
Total assets | 1,841,511 | 1,104,429 |
Current liabilities: | ||
Accounts payable | 17,693 | 1,541 |
Accrued expenses | 96,516 | 24,441 |
Deferred revenue, current portion | 3,246 | 1,746 |
Current portion of long-term debt, net | 13,334 | 89,419 |
Total current liabilities | 130,789 | 117,147 |
Deferred revenue, net of current portion | 2,253 | 2,530 |
Long-term debt, net | 1,492,766 | 787,255 |
Long-term debt, net | 30,433 | 544 |
Contingent liability | 15,472 | 0 |
Commitments and contingencies (Note 12) | ||
Stockholders’ equity: | ||
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December 31, 2022 and 2021, respectively | 135 | 138 |
Additional paid-in capital | 27,368 | 256,347 |
Accumulated other comprehensive loss | (922) | (620) |
Retained earnings (Accumulated deficit) | 143,217 | (58,912) |
Total stockholders’ equity | 169,798 | 196,953 |
Total liabilities and stockholders’ equity | $ 1,841,511 | $ 1,104,429 |